Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
18.72
0.08 (0.43%)
At close: Sep 05, 2025, 3:59 PM
18.72
0.00%
After-hours: Sep 05, 2025, 04:41 PM EDT
0.43% (1D)
| Bid | 17.86 |
| Market Cap | 1.53B |
| Revenue (ttm) | 305K |
| Net Income (ttm) | -344.06M |
| EPS (ttm) | -3.57 |
| PE Ratio (ttm) | -5.24 |
| Forward PE | -4.76 |
| Analyst | Buy |
| Ask | 19.57 |
| Volume | 772,224 |
| Avg. Volume (20D) | 881,882.8 |
| Open | 18.68 |
| Previous Close | 18.64 |
| Day's Range | 18.31 - 19.08 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.58 |
About VRDN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRDN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Viridian Therapeutics Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.02%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
+7.8%
Viridian Therapeutics shares are trading higher after the company announced positive long-term durability data from its THRIVE Phase 3 clinical trial of veligrotug in TED patients.
1 month ago · fool.com
Viridian (VRDN) Q2 Net Loss Widens 55%Viridian (VRDN) Q2 Net Loss Widens 55%
